{"id":560490,"date":"2025-11-14T00:00:00","date_gmt":"2025-11-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfcg0005-2025-biopharma-amyotrophic-lateral-sclerosis-landscape-forecast-niche-rare-disease-landscape-forecast-us\/"},"modified":"2026-04-29T11:16:37","modified_gmt":"2026-04-29T11:16:37","slug":"nrlfcg0005-2025-biopharma-amyotrophic-lateral-sclerosis-landscape-forecast-niche-rare-disease-landscape-forecast-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfcg0005-2025-biopharma-amyotrophic-lateral-sclerosis-landscape-forecast-niche-rare-disease-landscape-forecast-us\/","title":{"rendered":"Amyotrophic Lateral Sclerosis &#8211; Landscape &#038; Forecast &#8211; Niche &#038; Rare Disease Landscape &#038; Forecast (US\/EU5)"},"content":{"rendered":"<p>Amyotrophic lateral sclerosis (<abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>) is a disorder of the central nervous system characterized by motor neuron degeneration. <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> causes progressive weakness and atrophy of the muscles and loss of voluntary functions, including breathing, swallowing, and use of limbs, and eventually death. Three disease-modifying therapies are approved for <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> in the markets under study: riluzole (Sanofi\u2019s Rilutek, other brands, generics), Mitsubishi Tanabe Pharma\u2019s Radicava \/ Radicava ORS (edaravone), and Ionis Pharmaceuticals \/ Biogen\u2019s Qalsody (tofersen). Although the <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> pipeline comprises diverse drugs designed to enhance respiratory function, be neuroprotective, or restore lost neurons in the spinal cord, clinical success has been a formidable challenge, as evidenced by the late 2023 withdrawal of the <abbr title=\"biologics license application\">BLA<\/abbr> for BrainStorm Cell Therapeutics\u2019 NurOwn and the 2024 withdrawal of Amylyx Pharmaceuticals\u2019 Relyvrio (sodium phenylbutyrate and taurursodiol <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>) from the U.S. market. Thus, substantial clinical and commercial opportunity awaits developers of safe, effective therapies for this disease.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How will the size of the drug-treated <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> population change through 2034?<\/li>\n<li>What role do riluzole and Radicava \/ Radicava ORS play in the treatment of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>? How is Qalsody being incorporated into medical practice?<\/li>\n<li>Which therapies for <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> are likely to launch by 2034? What will their commercial impact be?<\/li>\n<li>Which emerging therapies are <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> experts most intrigued by or optimistic about? How would new therapies influence the management of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> patients?<\/li>\n<li>What are the key unmet needs in the treatment of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>?<\/li>\n<\/ul>\n<p><b>Content highlights<\/b><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Publication date<\/strong>: November 2025<\/li>\n<li><strong>Geography: <\/strong>United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr><\/li>\n<li><strong>Primary research:<\/strong> Country-specific interviews with thought-leading neurologists; survey data collected for this and other Clarivate research<\/li>\n<li><strong>Epidemiology: <\/strong>Diagnosed prevalent and drug-treated cases of ALS by country and subtype (i.e., familial and sporadic)<\/li>\n<li><strong>Forecast:<\/strong> Drug-level sales and patient share of key <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> therapies in 2024 and 2034<\/li>\n<li><strong>Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-560490","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-amyotrophic-lateral-sclerosis","biopharma-therapy-areas-neurology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/560490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/560490\/revisions"}],"predecessor-version":[{"id":575282,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/560490\/revisions\/575282"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=560490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}